The efficacy and safety of glucosamine hydrochloride tablets on uremia patients with knee osteoarthritis_West China Medical Journal

Authors：

 GU Jinhua , ZHAO Ping , WU Yalin

Department of Rheumatology and Immunology, the Second People’s Hospital of Yibin City, Yibin, Sichuan 644000, P. R. China;

Corresponding?author：

GU Jinhua, Email: gujinhua120@163.com

Keywords：

Glucosamine hydrochloride tablets; Uremia; Knee osteoarthritis; Therapeutic effect; Safety

DOI：

10.7507/1002-0179.201608162

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the treatment efficacy and safety of glucosamine hydrochloride tablets on uremia patients with knee osteoarthritis (OA). Methods A total of 118 uremia patients with knee OA were selected and randomly divided into the glucosamine hydrochloride tablets treatment group (treatment group) and the coated aldehyde oxystarch capsules group (control group) with 59 cases in each group. The course was 8 weeks. The Lequesne Index was assessed for curative effect evaluation, and the change of blood indexes was observed to evaluate drug safety. Results The total effective rate of Lequesne Index in the treatment group was 72.9%, while that in the control group was 13.6%; the difference was statistically significant (χ²=42.303, P<0.001). There was no significant change in the two groups before and after treatment in terms of the patients’ dialysis adequacy, routine blood, blood electrolytes, liver and kidney function (P>0.05). Conclusion Glucosamine hydrochloride tablets is curative and safe in the treatment of uremia patients with OA.

Citation： GU Jinhua, ZHAO Ping, WU Yalin. The efficacy and safety of glucosamine hydrochloride tablets on uremia patients with knee osteoarthritis. West China Medical Journal, 2017, 32(8): 1217-1220. doi: 10.7507/1002-0179.201608162 Copy

1.	中華醫學會風濕病學分會. 骨關節炎診斷及治療指南. 中華風濕病學雜志, 2010, 14(6): 416-419.
2.	胥少汀, 葛寶豐, 徐印坎. 實用骨科學. 北京: 人民軍醫出版社, 2010: 259-1339.
3.	Valdes AM, Spector TD. The genetic epidemiology of osteoarthritis. Curr Opin Rheumatol, 2010, 22(2): 139-143.
4.	Sanchez C, Mateus MM, Defresne MP, et al. Metabolism of human articular chondrocytes cultured in alginate beads. Longterm efects of interleukin 1 beta and nonsteroidal antiinflam-matory drugs. J Rheumatol, 2002, 29(4): 772-782.
5.	冷艷霞, 孫璐, 邸欣, 等. 鹽酸氨基葡萄糖片的相對生物利用度及其生物等效性評價. 沈陽藥科大學學報, 2006, 23(1): 6-9, 37.
6.	鄭昱新, 曹月龍, 石關桐, 等. 氨基葡萄糖對體外培養人軟骨和滑膜細胞軟骨寡聚基質蛋白分泌影響的比較. 中華風濕病學雜志, 2009, 13(5): 331-332.
7.	Barthe L, Woodley J, Lavit M, et al. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforschung, 2004, 54(5): 286-292.
8.	Aghazadeh-Habashi A, Jamali F. The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci, 2011, 14(2): 264-273.
9.	鮑運平, 易洋, 彭禮林, 等. 氨基葡萄糖對膝骨關節炎 SOD、MDA 影響的臨床研究. 長江大學學報: 自科版醫學下旬刊, 2013, 10(10): 1-2, 5.
10.	鮑運平, 喻愛喜, 杜娟, 等. 氨基葡萄糖對膝骨關節炎白細胞介素-6、血管內皮細胞生長因子影響的臨床研究. 臨床外科雜志, 2013, 21(1): 60-61.
11.	薛錚, 陳亞堃, 錢鈞強. 鹽酸氨基葡萄糖對膝骨關節炎患者關節液中 SOD 和 MDA 水平的影響. 中國藥師, 2012, 15(4): 540-542.
12.	羅從風, 曾炳芳. 硫酸氨基葡萄糖治療骨關節炎的臨床觀察. 國外醫學: 骨科學分冊, 2001, 22(3): 174.
13.	張鵬, 鄭昱新, 曹月龍, 等. 布洛芬與氨基葡萄糖對膝骨關節炎患者滑膜細胞增殖及軟骨寡聚基質蛋白表達影響的比較. 中華風濕病學雜志, 2010, 14(10): 668-671.
14.	Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med, 2003, 163(13): 1514-1522.
15.	楊南萍, 李江濤, 王玲, 等. 國產鹽酸氨基葡萄糖片治療膝骨性關節炎臨床觀察. 華西醫學, 2004, 19(4): 544-545.

1. 中華醫學會風濕病學分會. 骨關節炎診斷及治療指南. 中華風濕病學雜志, 2010, 14(6): 416-419.
2. 胥少汀, 葛寶豐, 徐印坎. 實用骨科學. 北京: 人民軍醫出版社, 2010: 259-1339.
3. Valdes AM, Spector TD. The genetic epidemiology of osteoarthritis. Curr Opin Rheumatol, 2010, 22(2): 139-143.
4. Sanchez C, Mateus MM, Defresne MP, et al. Metabolism of human articular chondrocytes cultured in alginate beads. Longterm efects of interleukin 1 beta and nonsteroidal antiinflam-matory drugs. J Rheumatol, 2002, 29(4): 772-782.
5. 冷艷霞, 孫璐, 邸欣, 等. 鹽酸氨基葡萄糖片的相對生物利用度及其生物等效性評價. 沈陽藥科大學學報, 2006, 23(1): 6-9, 37.
6. 鄭昱新, 曹月龍, 石關桐, 等. 氨基葡萄糖對體外培養人軟骨和滑膜細胞軟骨寡聚基質蛋白分泌影響的比較. 中華風濕病學雜志, 2009, 13(5): 331-332.
7. Barthe L, Woodley J, Lavit M, et al. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforschung, 2004, 54(5): 286-292.
8. Aghazadeh-Habashi A, Jamali F. The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci, 2011, 14(2): 264-273.
9. 鮑運平, 易洋, 彭禮林, 等. 氨基葡萄糖對膝骨關節炎 SOD、MDA 影響的臨床研究. 長江大學學報: 自科版醫學下旬刊, 2013, 10(10): 1-2, 5.
10. 鮑運平, 喻愛喜, 杜娟, 等. 氨基葡萄糖對膝骨關節炎白細胞介素-6、血管內皮細胞生長因子影響的臨床研究. 臨床外科雜志, 2013, 21(1): 60-61.
11. 薛錚, 陳亞堃, 錢鈞強. 鹽酸氨基葡萄糖對膝骨關節炎患者關節液中 SOD 和 MDA 水平的影響. 中國藥師, 2012, 15(4): 540-542.
12. 羅從風, 曾炳芳. 硫酸氨基葡萄糖治療骨關節炎的臨床觀察. 國外醫學: 骨科學分冊, 2001, 22(3): 174.
13. 張鵬, 鄭昱新, 曹月龍, 等. 布洛芬與氨基葡萄糖對膝骨關節炎患者滑膜細胞增殖及軟骨寡聚基質蛋白表達影響的比較. 中華風濕病學雜志, 2010, 14(10): 668-671.
14. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med, 2003, 163(13): 1514-1522.
15. 楊南萍, 李江濤, 王玲, 等. 國產鹽酸氨基葡萄糖片治療膝骨性關節炎臨床觀察. 華西醫學, 2004, 19(4): 544-545.

West China Medical Journal

The efficacy and safety of glucosamine hydrochloride tablets on uremia patients with knee osteoarthritis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content